(Reuters) - Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.
The drug, Firdapse, was being tested on seven patients with Musk-MG, a rare subpopulation of MG patients. There are currently no FDA approved therapies for this form of MG.
Catalyst’s shares jumped about 20 percent to $1.40 before the bell on Wednesday.
Reporting by Divya Grover in Bengaluru; Editing by Savio D'Souza